Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Phase 1

2(33.3%)

Phase 2

2(33.3%)

Early Phase 1

1(16.7%)

Phase 4

1(16.7%)

6Total

Phase 1(2)

Phase 2(2)

Early Phase 1(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT07532824Phase 1Recruiting

Proton-Based Total Marrow Irradiation for Allogeneic Transplantation in High-Risk AML/MDS

Role: lead

NCT06765876Early Phase 1Recruiting

CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial

Role: lead

NCT03551964Phase 4Completed

Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial Infarction

Role: collaborator

NCT06831799Completed

ERN-EuroBloodNet Registry on Patients With Rare Red Blood Cell Defects and COVID-19

Role: collaborator

NCT05054257Phase 1Recruiting

CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma

Role: lead

NCT04554459Phase 2Terminated

Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALL

Role: lead

NCT04554485Phase 2Completed

Blinatumomab Followed by High-dose Chemotherapy for Ph-negative Acute Lymphoblastic Leukemia (ALL)

Role: lead

NCT06281262Recruiting

Selected Immunological Indicators and Microbiota in Patients With Premature Birth and Preeclampsia

Role: collaborator

All 8 trials loaded